Adrenal mass (AM) is a common incidental finding detected during radiological investigations with an estimated incidence of 4%. Subjects with AM do not show any physical signs of adrenal hormonal excess, although they are often insulin resistant. Interestingly, apparently nonfunctioning AMs are often associated with a high prevalence of insulin resistance (IR) and metabolic syndrome. However, it is unclear whether AM develops from a primary IR and compensatory hyperinsulinemia or whether IR is only secondary to the slight cortisol hypersecretion by AM. Further, the degree of IR has been directly reported to correlate to the size of AM, thus allowing one to hypothesize that compensatory hyperinsulinemia to IR could be mitogenic on the adrenal cortex acting through the activation of insulin and insulinlike growth factor 1 receptors. Thus, the aim of the present article is to review the current evidence on the link between AM and compensatory hyperinsulinemia to IR.
W
ith advances in modern imaging technology, incidentally found adrenal mass (AM) has become an increasingly common management scenario for endocrinologists. The incidence of AM has been reported as high as 8% in autopsy series and 4% in radiologic series (1, 2) . Due to improved and widespread use of imaging techniques, the radiologic prevalence is expected to continue escalating, approaching the autopsy series. Also concerning is the evidence supporting an increased prevalence with age, with the risk of finding an AM being more common in the later years of life. In a rapidly aging society, the diagnosis and management of AM will become a more frequent task. AM management is still controversial, mostly because the associated morbidity is unknown.
By definition, patients with incidentally discovered AM do not show any physical signs of adrenal hormonal excess, although it has been associated with hypertension, dyslipidemia, glucose intolerance, and obesity that are all parameters closely linked to insulin resistance (IR) (3).
Thus, a tight association between AM and IR-related disease begs the following question: Is IR involved in the pathogenesis of AM or vice versa?
Clinical Evidence
AM has been reported to be associated with metabolic syndrome-related traits. Reincke et al. (4) assessed insulin sensitivity in subjects with AM finding that all the studied subjects were insulin resistant. This in vivo result was subsequently confirmed in vitro, finding that insulin was clearly able to stimulate the proliferation of NCI-H295R cells in a time-and dose-dependent manner (4) . An accurate assessment of insulin sensitivity using a hyperinsulinaemic euglycaemic clamp demonstrated that patients with AM were more insulin resistant than the matched control group (3). As well known, healthy overweight (not obese) subjects are expected to display an insulin sensitivity of ;7 mg/kg/min by hyperinsulinemic euglycemic clamp (5) . Nondiabetic subjects with AM displayed obesity-like (reduced) insulin sensitivity compared with matched healthy controls (6) . Making the distinction between peripheral (muscle) and central (hepatic) IR, patients with AM seem to have normal hepatic insulin sensitivity in a fasting condition, whereas they display peripheral (muscle) IR after glucose load (4). This metabolic phenotype resembles that of patients with type 2 diabetes (T2D), in which the primary deficiency in insulin action resides in the skeletal muscle (7) . The association between AM and glucose metabolism has been also suggested in a retrospective study assessing the prevalence of AM using abdominal computed tomography scan in a large cohort of T2D patients, reporting an increased prevalence of AM in diabetic patients compared with normal subjects (4.6% vs 0.6% to 4.0%) (8) . Similar results were reported in a prospective autoptic study, which showed a higher frequency of AM (16.5%) in patients with diabetes (9) in comparison with results obtained in the general population (a mean prevalence of AM of 2.3%) (10) .
The link between AM and glucose metabolism could recognize insulin as pivotal player. In fact, a direct correlation between the degree of IR and AM size assessed by computed tomography scan has been found (3). Further, a positive correlation between peripheral insulin sensitivity and adrenal sensitivity to adrenocorticotropic hormone (ACTH; calculated from the corticotropin-releasing hormone test) has been found in patients with nonfunctioning AM, thus suggesting that IR may inhibit the action of ACTH at the adrenal level, resulting in an increased level of plasma ACTH that, in turn, could overstimulate adrenal cortex and the formation of adenomas (ACTH resistance) (11) . In turn, the overstimulation of adrenal gland, besides causing adrenal growth, may also result in an overstimulation of cortisol secretion that could worsen a preexisting state of IR.
A significant correlation between the degree of IR and free urinary cortisol, ACTH, and serum cortisol level after dexamethasone suppression has been found in patients with AM; further, they showed slightly higher ACTH and cortisol levels after dexamethasone (1 mg) administration than control subjects. Although this difference did not reach statistical significance (possibly owing to the low sensitivity of the test to detect subtle cortisol hyper secretion), it suggested that there may be subtle disturbances in cortisol steroid secretion (3). These results were subsequently confirmed by Androulakis et al. (12) , who found an increased cardiovascular risk in patients with AM. This could be explained by the subtle cortisol secretion as documented by the higher area under the curve of cortisol after ACTH stimulation and urinary free cortisol in patients with AM compared with controls, although there was not a statistical difference. Using salivary cortisol as a tool to assess endogenous cortisol excess, patients with AM displayed higher morning and late-night salivary cortisol compared with controls (13) . These observations may suggest that patients with AM may have a cortisol hyperresponse to stimuli tests such as ACTH or to inhibition tests such as the dexhametasone test, although they may preserve a physiological rhythm of cortisol secretion. Patients with AM undergoing surgery for tumor size or growth experienced an improvement in blood pressure and fasting glucose, which are often associated with IR, even in the absence of any (causative) hormonal change (14) . The undetectable cortisol secretion may be responsible for IR encouraging visceral adipose tissue deposition as proven by the fact that patients with AM showed a higher total body fat, particularly abdominal fat (15) that tightly correlated to IR (3). Moreover, Iacobone et al. (16) reported that laparoscopic adrenalectomy was associated with a significant improvement of blood pressure and glycometabolic outcome in patients with AM compared with conservative treatment. Currently, there are two ongoing trials investigating whether adrenalectomy or conservative approach is more efficienct in preventing long-term metabolic consequences related to subclinical Cushing syndrome in patients with AM (ClinicalTrials.gov identifiers NCT02001051 and NCT01246739).
Basic Evidence
The involvement of insulin as a pivotal player in the pathogenesis of AM has been suggested by studies that demonstrated that insulin could stimulate carcinogenesis. In fact, insulin administration has been reported to cause mammary tumor growth in mice (17) and to promote aberrant crypt foci in the colon of rats (18, 19) .
Hyperinsulinemia contributes to the overexpression of insulinlike growth factor 1 receptors (IGF-1Rs) but also increases insulinlike growth factor (IGF)-1 levels that can bind to the receptor in the adrenal cortex (4). The latter is due to the upregulation of human hepatic growth hormone receptors and receptor-mediated growth hormone signaling in the liver, the main stimulus for IGF-1 release. Insulin also downregulates insulinlike growth factorbinding proteins (IGFBPs), in particular, IGFBP-1 and IGFBP-2, thereby increasing the extravascular availability of bioactive IGF-1 and IGF-2 and their tumourigenic properties (12) (Fig. 1) . IGF-2 has been reported to be overexpressed in adrenal carcinoma (20) (21) (22) (23) (24) . Only the paternal allele of the IGF-2 gene located at the locus 11p15 is expressed and is maternal (24) . The somatic structural alteration of the 11p15 locus, including loss of heterozygosity with paternal duplication of the allele, is the main cause of excessive transcriptional activation or loss of transcriptional suppression of IGF-2 (23, 25, 26) . This phenomenon is associated with a more aggressive phenotype of adrenal cancer and is considered one of the last steps of adrenal tumorigenesis (20, 21, 27) . In vitro studies showed an increased expression of IGF-2 in human adrenocortical cell lines NCI-H295R (28, 29) . Guillaud-Bataille et al. (30) detected a reduced proliferation, cell cycle arrest, and an increased apoptosis of NCI-H295R cells using a small-interfering RNA to inhibit the endogenous production of IGF-2. Moreover, no differences in terms of Weiss score, Ki67 index, European Network for the Study of Adrenal Tumors classification, overall survival, and disease-free survival have been found in patients with high IGF-2 expression compared with patients with low IGF-2 expression. The lack of specific molecular signatures in unsupervised analysis of microarray data from patients supported the absence of biological effects overexpression (30) . This hypothesis was confirmed in transgenic mice overexpressing IGFs that did not develop adrenal tumor but only hyperplasia of the zona fasciculate, thus suggesting that IGF-2 alone is not a tumor initiator but could have a role in tumor progression (31) (32) (33) .
Overexpression of both messenger RNA (mRNA) and the protein level of IGF-1R have been reported in adrenocortical carcinoma (ACC) (34, 35) . In particular, the overexpression of IGF-1R mRNA is elevated in pediatric ACC (36) and is associated with an increased risk to develop metastases (37) . In fact blocking this receptor by an antibody (38) or by a selective IGF-1R kinase inhibitor (NVP-AEW541) resulted in an arrest of proliferation of SW13 and of NCI-H295 cells and of pediatric ACC cell The compensatory hyperinsulinemia to IR increases the expression of IGF-1R and the binding of insulin to IGF-1R. Hyperinsulinemia also contributes to upregulate growth hormone receptor (GHR) and GHR-mediated signaling at the liver site, thus increasing IGF-1 production. The downregulation of IGFBPs secondary to hyperinsulinemia increased IGF-1 and IGF-2 availability. All these mechanisms encourage the adrenal cell growth. However, it could be also hypothesized that the first step could be represented by hyperinsulinemia and that AM could represent a pathological condition secondary to IR.
lines, respectively (37). Barlaskar et al. (36) performed experiments in a mouse xenografts model and in NCI-H295R cell aiming to reduce proliferation both in vitro and in.vivo arresting IGF pathway by blocking IGF-1R with a monoclonal antibody (IMC-A12) or with the tyrosine kinase inhibitor NVP-AEW541. Unsatisfactory results were obtained in a randomized, double-blind, placebo-controlled phase 3 trial (39) in which the administration of linsitinib (OSI-906), a strong inhibitor of both IGF-1R and IR, was not able to have an impact on disease progression of ACC (40, 41) .
The key molecule of IGF-1R pathway seems to be AKT in ACCs (Fig. 1) . The activation of IGF-1R has been associated with an increased level of activated AKT (pAKT) in NCI-H295R and SW13 cell lines (28, 36) . Fassnacht et al. (42) did not detect changes of ratio of pAKT/AKT mRNA level in ACC patients, although they reported a strong pAKT staining at the protein level in a small group of these patients, suggesting only a local activation of this pathway.
Several studies failed to detect any differences in IGF-1 expression between AM and normal adrenal glands (43) (44) (45) , except for a single immunohistochemical study that reported a higher IGF-1 expression in ACCs compared with benign adenomas (46) . A higher intensity of IR has been seen in carcinoma vs adenomas, although the IR expression was not related to the severity of pathological parameters. Finally, an increased expression of the IGFBP-2 protein was associated with high levels of IGF-2 in ACCs (47). This molecular phenotype seems to predict a malignant phenotype of ACCs (47) and an increased chance to develop metastasis (48) . The upregulation of IGFBP-2 has been correlated to morphological alteration and cell proliferation in an in vitro study on murine ACC cell line Y1 (49) .
Insulin Sensitizer Drugs as Potential Treatment of Adrenal Mass
Although chronic hyperinsulinemia observed in these patients could represent a factor that promotes tumor initiation and/or progression due to the mitogenic effect of insulin (50) (51) (52) or could be a consequence of IR caused by cortisol excess (10, 53) , it should be considered the key therapeutic target of the treatment of AM. In fact, blocking the excess of insulin could slow or arrest the growth of AM, or it could at least contribute to improve IR-related diseases such as dyslipidemia, hypertension, and T2D. Thus, the treatment of ACCs with insulinsensitizer drugs could represent a promising approach.
Metformin treatment has been reported to significantly reduce cell viability and proliferation in a dose-and time-dependent manner and to inhibit ERK1/2 and mTOR phosphorylation/activation, as well as the stimulation of AMPK activity. Metformin also has been reported to trigger the apoptotic pathway, shown by the decreased expression of Bcl-2 and HSP27, HSP60, and HSP70 and to enhance membrane exposure of annexin V, resulting in activation of caspase-3 apoptotic effector. Metformin also interfered with the proliferative autocrine loop of IGF2/ IGF-1R, which supports adrenal cancer growth. Finally, in the ACC xenograft mouse model, obtained by subcutaneous injection of H295R cells, metformin intraperitoneal administration inhibited tumor growth, confirmed by the significant reduction of Ki67% (54) .
Another insulin-sensitizer drug, rosiglitazone (RGZ), has been tested as a possible drug for the treatment of ACC (55) (56) (57) . RGZ is a ligand of peroxisome proliferatoractivated receptor (PPAR)-g, which is used in the treatment of T2D because of its ability to reduce IR. Moreover, RGZ exerts additional pleiotropic actions, such as the regulation of inflammation and cancer cell growth (58) . Although no differences of PPAR-g expression have been detected in normal and tumoral adrenal tissues, in vitro experiments demonstrated that RGZ may inhibit proliferation through the inhibition of the IGF-1R pathway in human NCI-H295R and SW13 ACC cells, without inhibiting the receptor itself (55, 56) . A study performed in a xenograft model of ACC in athymic mice further reported that the administration of RGZ causes a significant reduction of tumor growth and angiogenesis (57) . The lack of alteration in IGF-1R expression after treatment with RGZ may highlight the potential role of hyperinsulinemia in adrenal tumor promotion and/or progression through the mechanism previously described. Despite these encouraging results, the potential role of insulinsensitizer drugs as treatment for ACC has only been shown in cells and animal models, and no clinical evidence supported this hypothesis in human studies.
Conclusion
The current evidence is insufficient to clarify whether IR is the primary cause of AM or if it is secondary to cortisol secretion by AM. Longitudinal studies aiming to investigate the possible onset of IR in normoinsulinemic patients with nonfunctioning AM or, conversely, the possible development of AMs in subjects affected by hyperinsulinemia, may provide an answer to this question. Although this issue is still far from being clarified, an accurate assessment and possible treatment should be performed in patients with nonfunctioning AM.
